Skip to content
Politically.com Search all
Menu

2025 · 4th Quarter (Oct 1 - Dec 31)

GILEAD SCIENCES, INC.

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
4th Quarter - Report
Posted
Jan 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
e4edb173-018a-4524-aa24-f4d7493b7f3e
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

MMM · Medicare/Medicaid

Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Literal federal measure citations: S. 832, H.R. 1492

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.